ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.70
      0.13%
      US Tech 100
      17,617.60
      0.04%
      Dow Jones
      38,884.26
      0.08%
      Brent Oil
      82.865
      -0.73%
      Bitcoin
      62,373.10
      -1.26%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Merrimack Pharmaceuticals Inc (MACK)

      7. Merrimack Pharmaceuticals Inc (MACK) News

      MACK

      Merrimack Pharmaceuticals (MACK)

      Merrimack Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MACK
      DateTimeSourceHeadlineSymbolCompany
      12:51PMiHub NewswireFeaturedCannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa
      04/30/20245:15PMBusiness WireMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/27/20244:30PMBusiness WireMerrimack Receives $225 Million Milestone Payment from IpsenNASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/07/20244:42PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/07/20244:39PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/07/20244:30PMBusiness WireMerrimack Reports Full Year 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/07/20244:15PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/07/202412:29PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      03/05/20244:44PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      02/22/20244:46PMEdgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      02/14/20244:20PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      02/13/20244:26PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MACKMerrimack Pharmaceuticals Inc
      02/13/20244:22PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
      02/13/20244:18PMBusiness WireMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)NASDAQ:MACKMerrimack Pharmaceuticals Inc
      01/31/20242:08PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      01/25/20244:05PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      12/28/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
      12/13/20234:05PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      12/11/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
      11/20/20236:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
      11/16/20235:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
      11/02/20234:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      11/02/20234:30PMBusiness WireMerrimack Reports Third Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      08/14/20234:05PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      08/09/20234:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
      08/03/20234:36PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
      08/03/20234:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MACKMerrimack Pharmaceuticals Inc
      08/03/20234:30PMBusiness WireMerrimack Reports Second Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
      06/08/20234:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MACKMerrimack Pharmaceuticals Inc
      06/08/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MACKMerrimack Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:MACK